About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Apc
APC, WNT signaling pathway regulator
MGI:88039
231 phenotypes from 25 alleles in 56 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
ApcGt(XA018)Byg/Apc+
(B6.129P2-ApcGt(XA018)Byg x C3H/HeJ)F1 		decreased tumor growth/size J:202877
ApcGt(XA018)Byg/Apc+
B6.129P2-ApcGt(XA018)Byg 		increased colon adenoma incidence J:202877
increased intestinal adenoma incidence J:202877
increased tumor growth/size J:202877
intestine polyps J:202877
ApcM1Tno/Apc+
either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl) 		increased mammary adenocarcinoma incidence J:218227
increased mammary gland tumor incidence J:218227
increased osteoma incidence J:218227
increased osteosarcoma incidence J:218227
increased pilomatricoma incidence J:218227
increased skin tumor incidence J:218227
increased trichoepithelioma incidence J:218227
premature death J:218227
ApcM1Tno/Apc+
involves: C57BL/6 * DBA/2JJcl 		increased mammary gland tumor incidence J:218227
increased osteoma incidence J:218227
increased skin tumor incidence J:218227
premature death J:218227
ApcM1Tno/ApcM1Tno
involves: C57BL/6 * DBA/2JJcl 		embryonic lethality during organogenesis, complete penetrance J:218227
ApcMin/Apc+
(AKR/J x C57BL/6J-ApcMin)F1 		aneuploidy J:21369
decreased intestinal adenoma incidence J:1879
extended life span J:1879
increased incidence of tumors by chemical induction J:15101
increased intestinal adenocarcinoma incidence J:21369
ApcMin/Apc+
(MA/MyJ x C57BL/6J-ApcMin)F1 		decreased intestinal adenoma incidence J:1879
extended life span J:1879
ApcMin/Apc+
B6(AKR)-ApcMin 		abnormal pregnancy J:10209
anemia J:10209
increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
increased mammary gland tumor incidence J:15101
mammary gland hyperplasia J:15101
premature death J:10209
ApcMin/Apc+
B6.Cg-Brca2tm1Mbn ApcMin 		abnormal mammary gland development J:67445
abnormal ovarian follicle morphology J:67445
abnormal ovarian folliculogenesis J:67445
abnormal vagina epithelium morphology J:67445
absent corpus luteum J:67445
absent mature ovarian follicles J:67445
absent nipple J:67445
adrenal gland hyperplasia J:67445
decreased body weight J:67445
increased incidence of induced tumors J:67445
increased mammary gland tumor incidence J:67445
ovary atrophy J:67445
normal reproductive system phenotype J:67445
uterus atrophy J:67445
ApcMin/Apc+
C57BL/6J-ApcMin 		decreased macrophage cell number J:85142
hepatic steatosis J:86036
increased circulating free fatty acids level J:86036
increased circulating triglyceride level J:86036
increased colon adenoma incidence J:158733, J:160399
increased intestinal adenoma incidence J:1879, J:85142, J:158733, J:241611
increased prostaglandin level J:85142
postnatal growth retardation J:85142
premature death J:1879
ApcMin/Apc+
C57BL/6J-ApcMin/J 		abnormal interleukin secretion J:305794
increased colon adenoma incidence J:331404
increased intestinal adenoma incidence J:331404
premature death J:331404
ApcMin/Apc+
involves: 129 * C57BL/6 		decreased NK cell number J:156864
decreased splenocyte number J:156864
decreased T cell number J:156864
intestine polyps J:156864
ApcMin/Apc+
involves: 129P2/OlaHsd * C57BL/6 		increased intestinal adenoma incidence J:95893
normal neoplasm J:95893
ApcMin/Apc+
involves: AKR/J * C57BL/6J 		anemia J:10209
decreased hematocrit J:10209
hyperlipidemia J:10209
increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
melena J:10209
premature death J:10209
ApcMin/Apc+
involves: C57BL/6 * C57BL/6J 		intestine polyps J:134087
premature death J:134087
ApcMin/Apc+
involves: C57BL/6J 		abnormal enterocyte proliferation J:118600
abnormal intestinal goblet cell morphology J:118600
abnormal intestinal mucosa morphology J:118600
abnormal large intestine crypts of Lieberkuhn morphology J:118600
abnormal tumor pathology J:268691
anemia J:75393
decreased intestinal adenoma incidence J:268691
decreased tumor growth/size J:268691
increased intestinal adenoma incidence J:75393, J:94108, J:299895
increased mammary adenocarcinoma incidence J:94108
intestinal obstruction J:75393
intestine polyps J:191217
premature death J:75393, J:94108
rectal prolapse J:94108
ApcMin/Apc+
Tg(Rorc-EGFP)1Ebe/?
involves: C57BL/6 		abnormal effector T cell morphology J:137020
colon polyps J:137020
enlarged mesenteric lymph nodes J:137020
intestine polyps J:137020
lymph node hyperplasia J:137020
ApcMin/ApcMin
involves: AKR/J * C57BL/6J 		abnormal egg cylinder morphology J:27993
abnormal embryo development J:27993
abnormal embryo size J:27993
ApcMin/ApcMin
involves: C57BL/6 * POMOD 		abnormal embryo development J:27993
decreased embryo size J:27993
embryonic lethality between implantation and placentation J:27993
embryonic lethality, complete penetrance J:27993
ApcMin/ApcMin
involves: C57BL/6J 		abnormal cell physiology J:187862
ApcMin/ApcMin
involves: C57BL/6J * CAST/EiJ 		embryonic lethality, complete penetrance J:27993
ApcMin/Apctm1.1Klne
B6.Cg-ApcMin/Apctm1.1Klne 		abnormal enterocyte proliferation J:186132
intestine polyps J:186132
ApcMin/Apctm1Tno
involves: 129 * 129S4/SvJae * C57BL/6 		abnormal brain development J:156864
absent forebrain J:156864
absent mandible J:156864
absent midbrain J:156864
acrania J:156864
lethality throughout fetal growth and development, incomplete penetrance J:156864
perinatal lethality, complete penetrance J:156864
Apctm1.1Alew/Apc+
B6.129-Apctm1.1Alew 		abnormal tumor morphology J:180275
anemia J:180275
gastrointestinal tract polyps J:180057, J:180275
increased adenoma incidence J:180057
increased apoptosis J:180275
increased cell proliferation J:180275
increased intestinal adenoma incidence J:180057, J:180275
premature death J:180275
Apctm1.1Alew/Apctm1.1Alew
B6.129-Apctm1.1Alew 		prenatal lethality, complete penetrance J:180057
Apctm1.1Klne/Apctm1.1Klne
B6.129-Apctm1.1Klne 		abnormal enterocyte proliferation J:186132
colon polyps J:186132
gastric polyps J:186132
Apctm1.1Rsmi/Apc+
involves: 129P2/OlaHsd 		increased gastrointestinal tumor incidence J:149225
Apctm1.1Rsmi/Apc+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		anemia J:159883
increased desmoid tumor incidence J:159883
increased gastrointestinal tumor incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
intestinal obstruction J:159883
premature death J:159883
skin cyst J:159883
Apctm1.1Tno/Apc+
involves: 129S4/SvJae * C57BL/6 		anemia J:127452
gastrointestinal hemorrhage J:127452
increased intestinal adenoma incidence J:127452
intestinal obstruction J:127452
intestine polyps J:127452
premature death J:127452
Apctm1.1Tno/Apctm1Tno
involves: 129 * 129S4/SvJae * BALB/cJ * C57BL/6 		abnormal brain development J:156864
absent forebrain J:156864
absent mandible J:156864
absent midbrain J:156864
acrania J:156864
perinatal lethality, complete penetrance J:156864
Apctm1.1Tyj/Apc+
involves: 129S4/SvJaeSor * C57BL/6 		anemia J:160399
increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
increased tumor growth/size J:160399
premature death J:160399
Apctm1Cip/Apc+
involves: 129P2/OlaHsd * C57BL/6 		anemia J:94108
increased colon adenoma incidence J:94108
increased intestinal adenocarcinoma incidence J:94108
increased intestinal adenoma incidence J:94108
increased mammary adenocarcinoma incidence J:94108
premature death J:94108
rectal hemorrhage J:94108
rectal prolapse J:94108
Apctm1Cip/Apctm1Cip
involves: 129P2/OlaHsd * C57BL/6 		prenatal lethality, complete penetrance J:94108
Apctm1Kk/Apctm1Kk
Tg(Lck-cre)1Cwi/?
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 		abnormal intestinal mucosa morphology J:104334
abnormal T cell differentiation J:100461
arrested T cell differentiation J:100461
increased circulating tumor necrosis factor level J:128606
increased double-negative T cell number J:100461
increased intestinal adenoma incidence J:104334
increased mast cell number J:128606
intestine polyps J:128606
small thymus J:100461
thymus hypoplasia J:100461
Apctm1Mmt/Apc+
involves: 129S2/SvPas * C57BL/6J 		increased intestinal adenoma incidence J:25200, J:79668
intestine polyps J:79668
Apctm1Mmt/Apctm1Mmt
involves: 129S2/SvPas * C57BL/6J 		embryonic lethality between implantation and somite formation, incomplete penetrance J:25200
Apctm1Rak/Apc+
(C57BL/6J x 129P2/OlaHsd)F1 		epidermal cyst J:151494
increased desmoid tumor incidence J:151494
increased gastrointestinal tumor incidence J:151494
increased stomach tumor incidence J:151494
premature death J:151494
Apctm1Rak/Apc+
B6.129P2-Apctm1Rak 		colon polyps J:107273
decreased tumor-free survival time J:107273
gastric polyps J:107273
intestine polyps J:107273
Apctm1Rak/Apc+
involves: 129P2/OlaHsd * C57BL/6 		increased hepatocellular carcinoma incidence J:20443
increased intestinal adenocarcinoma incidence J:20443
increased intestinal adenoma incidence J:20443
premature death J:20443
rectal hemorrhage J:20443
Apctm1Rak/Apc+
involves: 129P2/OlaHsd * C57BL/6J 		increased intestinal adenocarcinoma incidence J:65142
increased stomach tumor incidence J:65142
Apctm1Rak/Apctm1Rak
involves: 129P2/OlaHsd * C57BL/6 		embryonic lethality, complete penetrance J:20443
Apctm1Rfo/Apctm1Rfo
B6.129P2-Apctm1Rfo 		postnatal lethality, incomplete penetrance J:55416
Apctm1Rfo/Apctm1Rfo
involves: 129P2/OlaHsd 		normal cellular phenotype J:116121
Apctm1Rfo/Apctm1Rfo
involves: 129P2/OlaHsd * C57BL/6J 		absent male preputial gland J:55416
decreased body size J:55416
normal mortality/aging J:55416
normal neoplasm J:55416
postnatal growth retardation J:55416
skin cyst J:55416
Apctm1Rsmi/Apc+
Tg(Fabp1-cre)1Jig/0
involves: 129P2/OlaHsd * FVB/N 		increased gastrointestinal tumor incidence J:159883
increased intestinal adenocarcinoma incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
increased tumor-free survival time J:159883
Apctm1Rsmi/Apctm1Rsmi
involves: 129P2/OlaHsd 		normal neoplasm J:149225
no abnormal phenotype detected J:149225
Apctm1Rsmi/Apctm1Rsmi
Pgrtm2(cre)Lyd/Pgr+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J 		abnormal internal female genitalia morphology J:210095
abnormal oviduct morphology J:210095
endometrium hyperplasia J:210095
increased granulosa cell tumor incidence J:210095
increased ovary tumor incidence J:210095
increased reproductive system tumor incidence J:210095
ovary cyst J:210095
Apctm1Rsmi/Apctm1Rsmi
Tg(Col2a1-cre)1Rsjo/0
involves: 129P2/OlaHsd * FVB/N 		abnormal abdominal wall morphology J:149225
abnormal bone mineralization J:149225
abnormal cartilage development J:149225
abnormal chondrocyte morphology J:149225
abnormal craniofacial morphology J:149225
abnormal cranium morphology J:149225
abnormal endochondral bone ossification J:149225
abnormal forelimb morphology J:149225
abnormal hindlimb morphology J:149225
abnormal humerus morphology J:149225
abnormal limb development J:149225
abnormal mandible morphology J:149225
abnormal rib morphology J:149225
abnormal skeleton development J:149225
abnormal thoracic cavity morphology J:149225
absent sternum J:149225
blistering J:149225
decreased body length J:149225
decreased fetal size J:149225
enhanced osteoblast differentiation J:149225
perinatal lethality, incomplete penetrance J:149225
postnatal lethality, complete penetrance J:149225
scapular bone hypoplasia J:149225
short forelimb J:149225
short hindlimb J:149225
short ribs J:149225
Apctm1Tno/Apc+
involves: 129 * 129S4/SvJae * C57BL/6 		increased hepatocellular carcinoma incidence J:156864
Apctm1Tno/Apc+
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * C57BL/6 * SJL 		anemia J:126018
increased gastrointestinal tumor incidence J:126018
increased small intestine adenocarcinoma incidence J:126018
postnatal growth retardation J:126018
Apctm1Tno/Apc+
Tg(CDX2-cre)101Erf/0
involves: 129S4/SvJae * C57BL/6 * SJL 		anemia J:126018
decreased body weight J:126018
decreased hematocrit J:126018
increased gastrointestinal tumor incidence J:126018
increased mammary adenocarcinoma incidence J:126018
increased tumor incidence J:126018
intestinal obstruction J:126018
premature death J:126018
rectal prolapse J:126018
Apctm1Tno/Apc+
Tg(CDX2-cre*)189Erf/0
involves: 129S4/SvJae * C57BL/6 * SJL 		normal neoplasm J:148161
Apctm1Tno/Apc+
Tg(CDX2-cre/ERT)#Erf/0
involves: 129S4/SvJae 		increased gastrointestinal tumor incidence J:189226
Apctm1Tno/Apctm1Tno
involves: 129 * 129S4/SvJae * C57BL/6 		increased hepatocellular carcinoma incidence J:156864
increased incidence of tumors by chemical induction J:156864
Apctm1Tno/Apctm1Tno
involves: 129S4/SvJae * C57BL/6 		increased colon adenoma incidence J:43301
Apctm1Tno/Apctm1Tno
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		increased intestinal adenoma incidence J:227334
Apctm1Tno/Apctm1Tno
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * ICR 		decreased body weight J:95502
enlarged kidney J:95502
increased blood urea nitrogen level J:95502
increased renal cystadenoma incidence J:95502
kidney cyst J:95502
polycystic kidney J:95502
postnatal lethality, incomplete penetrance J:95502
premature death J:95502
Apctm1Tno/Apctm1Tno
Tg(CDX2-cre)101Erf/0
involves: 129S4/SvJae * C57BL/6 * SJL 		embryonic lethality, complete penetrance J:126018
Apctm1Tno/Apctm1Tno
Tg(CDX2-cre*)189Erf/0
involves: 129S4/SvJae * C57BL/6 * SJL 		increased colon adenoma incidence J:148161
intestine polyps J:148161
kinked tail J:148161
postnatal lethality, complete penetrance J:148161
premature death J:148161
short tail J:148161
Apctm1Tno/Apctm1Tno
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129S4/SvJae * C57BL/6 * CBA 		abnormal urinary bladder urothelium morphology J:164579
Apctm1Tno/Apctm1Tno
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2 		increased prostate gland adenocarcinoma incidence J:120308
increased prostate intraepithelial neoplasia incidence J:120308
increased tumor incidence J:120308
premature death J:120308
prostate gland epithelial hyperplasia J:120308
Apctm1Tno/Apctm1Tno
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * C57BL/6 * SJL 		embryonic lethality, complete penetrance J:126018
Apctm1Tyj/Apc+
Tg(Vil1-cre)20Syr/0
involves: C57BL/6 * DBA/2 		increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm1Tyj/Apctm1Tyj
involves: 129P2/OlaHsd * C57BL/6 		no abnormal phenotype detected J:159014
Apctm2.1Alew/Apc+
B6.129-Apctm2.1Alew 		abnormal tumor pathology J:180057
anemia J:180057
gastrointestinal tract polyps J:180057
hunched posture J:180057
increased adenoma incidence J:180057
increased intestinal adenoma incidence J:180057
Apctm2.1Alew/Apctm2.1Alew
B6.129-Apctm2.1Alew 		prenatal lethality, complete penetrance J:180057
Apctm2.1Cip/Apc+
Tg(Fabp1-cre)1Jig/0
involves: 129P2/OlaHsd * FVB/N 		increased intestinal adenocarcinoma incidence J:132357
Apctm2.1Cip/Apc+
Tg(Vil1-cre)20Syr/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm2.1Cip/Apc+
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		abnormal autophagy J:227287
abnormal gut flora balance J:227287
cachexia J:227287
decreased tumor-free survival time J:227287
increased colon adenoma incidence J:227287
increased intestinal adenoma incidence J:227287
intestine polyps J:227287
rectal prolapse J:227287
Apctm2.1Cip/Apc+
Lgr5tm1(cre/ERT2)Cle/Lgr5+
involves: 129P2/OlaHsd * C57BL/6 		normal neoplasm J:186084
Apctm2.1Cip/Apc+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+
involves: 129 * 129P2/OlaHsd * C57BL/6 		increased intestinal adenoma incidence J:186084
Apctm2.1Cip/Apctm2.1Cip
involves: 129P2/OlaHsd * C57BL/6N 		increased hepatocellular carcinoma incidence J:94721
liver hyperplasia J:94721
premature death J:94721
Apctm2.1Cip/Apctm2.1Cip
Tg(Ttr-cre/Esr1*)1Vco/0
B6.Cg-Apctm2.1Cip Tg(Ttr-cre/Esr1*)1Vco 		abnormal liver morphology J:184496
abnormal NK T cell physiology J:184496
decreased NK T cell number J:184496
enlarged liver J:184496
increased interferon-gamma secretion J:184496
increased interleukin-4 secretion J:184496
liver inflammation J:184496
Apctm2.1Cip/Apctm2.1Cip
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		abnormal colon morphology J:98469
abnormal intestinal epithelium morphology J:98469
abnormal intestinal goblet cell morphology J:98469
abnormal intestine development J:98469
abnormal small intestine crypts of Lieberkuhn morphology J:98469
increased small intestinal crypt cell apoptosis J:98469
premature death J:98469
Apctm2.1Rak/Apc+
involves: 129/Sv * C57BL/6J * SJL 		abnormal nursing J:114152
anemia J:114152
increased gastrointestinal tumor incidence J:114152
increased intestinal adenoma incidence J:114152
premature death J:114152
rectal hemorrhage J:114152
Apctm2Mmt/Apc+
involves: 129X1/SvJ 		increased intestinal adenoma incidence J:81402
Apctm2Mmt/Apctm2Mmt
involves: 129X1/SvJ 		embryonic lethality J:81402
Apctm2Mmt/Apctm3Mmt
involves: 129X1/SvJ * C57BL/6N 		abnormal egg cylinder morphology J:81402
abnormal embryonic epiblast morphology J:81402
abnormal embryonic tissue morphology J:81402
Apctm2Rak/Apc+
Tg(Car1-cre)5Flt/0
involves: 129/Sv * C57BL/6J * SJL 		anemia J:164247
colon polyps J:164247
decreased hematocrit J:164247
normal homeostasis/metabolism phenotype J:164247
increased incidence of tumors by chemical induction J:164247
increased intestinal adenoma incidence J:164247
melena J:164247
normal neoplasm J:164247
Apctm2Rak/Apctm2.1Rak
involves: 129/Sv * C57BL/6J * SJL 		no abnormal phenotype detected J:114152
Apctm2Rak/Apctm2Rak
involves: 129/Sv * C57BL/6J * SJL 		increased carcinoma incidence J:156532
increased colon adenoma incidence J:156532
increased organ/body region tumor incidence J:156532
Apctm2Rak/Apctm2Rak
Tg(Car1-cre)5Flt/0
involves: 129/Sv * C57BL/6J * SJL 		decreased body weight J:164247
decreased hematocrit J:164247
increased intestinal adenoma incidence J:164247
premature death J:164247
rectal prolapse J:164247
Apctm2Rak/Apctm2Rak
Tg(KRT14-cre)8Brn/0
involves: 129/Sv * C57BL/6J * FVB/N * SJL 		abnormal cell proliferation J:114152
abnormal ear shape J:114152
abnormal hair follicle bulb morphology J:114152
abnormal hair follicle development J:114152
abnormal hair follicle morphology J:114152
abnormal hair follicle orientation J:114152
abnormal Hassall's corpuscle morphology J:114152
abnormal keratinocyte differentiation J:114152
abnormal skin pigmentation J:114152
abnormal thymus morphology J:114152
abnormal tooth development J:114152
absent teeth J:114152
absent upper incisors J:114152
blepharoptosis J:114152
cornea epithelium hyperplasia J:114152
decreased body size J:114152
decreased thymocyte number J:114152
delayed hair appearance J:114152
Harderian gland hyperplasia J:114152
increased ear pigmentation J:114152
increased forehead pigmentation J:114152
lethargy J:114152
postnatal lethality, complete penetrance J:114152
salivary gland epithelial hyperplasia J:114152
scaly skin J:114152
short hair J:114152
short vibrissae J:114152
skin ridges J:114152
small stomach J:114152
small thymus J:114152
underdeveloped hair follicles J:114152
weight loss J:114152
wrinkled skin J:114152
Apctm2Rak/Apctm2Rak
Tg(Pdx1-cre)6Tuv/0
involves: 129/Sv * C57BL/6J * FVB/N * SJL 		abnormal intestine development J:234310
abnormal pancreas development J:234310
decreased pancreatic beta cell mass J:234310
decreased pancreatic islet number J:234310
duodenal atresia J:234310
neonatal lethality, complete penetrance J:234310
Apctm2Rfo/Apc+
129P2/OlaHsd-Apctm2Rfo 		increased gastrointestinal tumor incidence J:151494
increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494
premature death J:151494
Apctm2Rfo/Apc+
(C57BL/6J x 129P2/OlaHsd)F1 		epidermal cyst J:151494
increased desmoid tumor incidence J:151494
increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494, J:204440
increased mammary gland tumor incidence J:151494
increased metastatic potential J:204440
increased tumor incidence J:151494
premature death J:151494
Apctm2Rfo/Apc+
B6.129P2-Apctm2Rfo 		increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494
increased mammary gland tumor incidence J:151494
premature death J:151494
Apctm2Rfo/Apctm2Rfo
B6.129P2-Apctm2Rfo 		postnatal lethality, complete penetrance J:151494
Apctm2Tno/Apc+
involves: C57BL/6J 		hepatic steatosis J:86036
hyperlipidemia J:86036
increased circulating cholesterol level J:86036
increased circulating free fatty acids level J:86036
increased circulating triglyceride level J:86036
intestine polyps J:86036
Apctm2Tno/Apc+
Not Specified 		increased intestinal adenoma incidence J:47857
premature death J:47857
Apctm3Mmt/Apc+
B6.129X1-Apctm3Mmt 		increased intestinal adenoma incidence J:101604
intestine polyps J:101604
Apctm3Mmt/Apc+
involves: 129X1/SvJ * C57BL/6N 		intestine polyps J:81402
Apctm3Mmt/Apctm3Mmt
involves: 129X1/SvJ * C57BL/6N 		abnormal anterior visceral endoderm morphology J:81402
abnormal brain development J:81402
abnormal developmental patterning J:81402
abnormal endocardial heart tube morphology J:81402
abnormal floor plate morphology J:81402
abnormal foregut morphology J:81402
abnormal head development J:81402
abnormal hindbrain development J:81402
abnormal mesendoderm development J:81402
abnormal neural tube morphology J:81402
abnormal primitive node morphology J:81402
absent forebrain J:81402
absent midbrain J:81402
absent neural folds J:81402
cardia bifida J:81402
embryonic lethality during organogenesis, complete penetrance J:81402
embryonic-extraembryonic boundary constriction J:81402
incomplete embryo turning J:81402
rostral body truncation J:81402
rostral-caudal axis duplication J:81402
split notochord J:81402
Apctm4Mmt/Apc+
B6.129X1-Apctm4Mmt 		increased intestinal adenoma incidence J:101604
intestine polyps J:101604
Apctm4Mmt/Apctm4Mmt
B6.129X1-Apctm4Mmt 		embryonic lethality during organogenesis, complete penetrance J:101604
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory